METHOD FOR EVALUATING THE SOLUBILITY OF A CRYSTALLINE SUBSTANCE IN A POLYMER

A method for evaluating the solubility of a crystalline substance in a polymer comprises a) providing at least one sample of an intimate crystalline substance/polymer mixture at a predetermined crystalline substance concentration; b) annealing the sample at a constant temperature Tfor a period of time; c) heating the annealed sample while recording the heat flux over time by DSC; d) identifying a DSC dissolution endotherm in the recorded heat flux, if any; e) considering the crystalline substance concentration as a concentration above the crystalline substance solubility in the polymer at temperature Twhen there is a DSC dissolution endotherm identified, and considering the crystalline substance concentration as a concentration less than or equal to the crystalline substance solubility in the polymer at temperature Twhen there is no DSC dissolution endotherm identified. Thus, the method yields the upper and lower bounds for the equilibrium solubility at a given temperature or the upper and lower bounds for the equilibrium solubility temperature at a given crystalline substance concentration. The method improves accuracy of measurement near the glass transition temperature. 1. A method for evaluating the solubility of a crystalline substance in a polymer , comprisinga) providing at least one sample of an intimate crystalline substance/polymer mixture at a predetermined crystalline substance concentration;{'sub': 'a', 'b) annealing the sample at a constant temperature Tfor a period of time;'}c) heating the annealed sample while recording the heat flux over time by DSC;d) identifying a DSC dissolution endotherm in the recorded heat flux, if any;{'sub': a', 'a, 'e) considering the crystalline substance concentration as a concentration above the crystalline substance solubility in the polymer at temperature Twhen there is a DSC dissolution endotherm identified, and considering the crystalline substance concentration as a concentration less than or equal to the ...

Whisker Manufacturing, Detection, Response, and Compound Manufacturing Apparatus and Method

An invention for making productive uses of normally undesirable whiskers is provided. Embodiments of the invention include a variety of apparatuses and methods associated with forming and using whiskers as well as forming whisker compounds is disclosed. For example, whisker detection modules can be created which provide a whisker surveillance capability. The whisker detection modules can further be coupled with a whisker response system such as an alarm or insulating material dispersing system. Another aspect of the invention is providing a variety of environments or microenvironments with regard to a whisker forming structure to affect whisker creation such as maximizing whisker formation. Another example includes provision of a variety of embodiments for manufacturing compounds of whiskers of various metal and metal alloys, including structures and methods is provided. Whisker compounds produced using various embodiments of the invention can be used for various applications.

Bundle with different information leaflets and method for producing such a bundle

A method for producing a bundle ( 2 ) of different information leaflets ( 3, 4 ) from a sheet of flat material having at least two different sections, and a bundle ( 2 ) of such leaflets. The information leaflets ( 3, 4 ) are folded jointly and a protruding fold ( 14 ) is cut for separation of the information leaflets ( 3, 4 ).

Verfahren zur Verbesserung der Stabilität von Polyolefinen

Method for evaluating the solubility of a crystalline substance in a polymer

A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning Calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices. The method relies on the detection of the dissolution endpoint of a drug/polymer mixture prepared by cryomilling.

Method of producing a polyetheramine

HYDROPHILE POLYESTER MOLDING.

Itraconazole compositions with improved bioavailability

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35 > .DELTA.Htr (1) (wherein .DELTA.Htr represents the endotherm (J/g) accompanying a transition at about 240~ C). The solid dispersion product shows an improved bioavailability.

Hardening of fatty acid fats or unsaturated fatty acid esters

Pharmaceutical dosage form comprising polymeric carrier composition

A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95 % by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight- average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.

Method for evaluating the solubility of a crystalline substance in a polymer

A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning Calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices. The method relies on the detection of the dissolution endpoint of a drug/polymer mixture prepared by cryomilling.

Process for improving the stability of polyolefins

Process for the preparation of polyacyloxamidrazones

Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier

The invention concerns a method for producing solid galenic formulations which consists in: forming a processable paste comprising a) 50 to 99.4 wt. % of at least one non-thermoplastic carrier, b) 0.5 to 30 wt. % of at least an adjuvant selected among thermoplastic polymers, lipids, sugar alcohols and solubilizing agents, c) 0.1 to 49.5 wt. % of at least one active principle, at a temperature not less than the softening temperature of the adjuvant but rising to at least 70 ~C; then in cooling the resulting paste. Said solid galenic formulations quickly disintegrate in an aqueous medium.

Explosive neutralizer and method

An explosive device includes a firing train, an explosive charge and a shock activated neutralizer configured to disable activation of the explosive charge by the firing train. The neutralizer includes a housing and a rupturable fluid barrier configured to selectively permit mixing of disabling material constituents to interact with the firing train to disable the same. A method of neutralizing an explosive device includes rupturing the fluid barrier, at least in part by applying a shock to the explosive device, and interacting the disabling material with the firing train to disable the same.

dosage form and method for the delivery of drugs of abuse

FORMA DE DOSAGEM E MéTODO PARA A DISTRIBUIçAO DE FáRMACOS DE ABUSO Uma forma de dosagem e método para a distribuiçãode fármacos, particularmente fármacos de abuso, caracteriza- da por resistência a extração por solvente, adulteração, esmagar, ou moer, e fornecer uma explosão inicial de liberação de fármaco seguida pelo período prolongado de liberação controlável d fármaco. DOSAGE FORM AND METHOD FOR THE DISTRIBUTION OF ABUSE DRUGS A dosage form and method for the distribution of drugs, particularly drugs of abuse, characterized by resistance to solvent extraction, adulteration, crushing, or grinding, and providing an initial explosion of drug release followed by the prolonged period of controllable drug release.

door holder

Hydro rope elevator

Process for the production of carbon disulfide from trithiane

Dosage forms with improved bioavailability

A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>ΔH tr (1) (wherein ΔH tr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.

Process for the preparation of aqueous ammonium rhodanide solutions

DEVICE FOR DETERMINING THE POSITION OF DOWEL HOLES.

Process for the preparation of 4-methylpentene-1

Method for producing solid galentic formulations using a crosslinked non-thermoplastic carrier

Production of a solid dosage form (A) involves: (1) forming a shapable mass comprising (by weight) 50-99.4% crosslinked, non-thermoplastic carrier (I), 0.5-30 wt. % adjuvant(s) (II) selected from thermoplastic polymers, lipids, sugar alcohols (or derivatives) and solubilizers and 0.1-49.5% active agent(s) (III) at or above the softening point of (II) (but at 70 degrees C or more); and (2) cooling.

Method for evaluating the solubility of a crystalline substance in a polymer

A method for evaluating the solubility of a crystalline substance in a polymer comprises a) providing at least one sample of an intimate crystalline substance/polymer mixture at a predetermined crystalline substance concentration; b) annealing the sample at a constant temperature T a for a period of time; c) heating the annealed sample while recording the heat flux over time by DSC; d) identifying a DSC dissolution endotherm in the recorded heat flux, if any; e) considering the crystalline substance concentration as a concentration above the crystalline substance solubility in the polymer at temperature T a when there is a DSC dissolution endotherm identified, and considering the crystalline substance concentration as a concentration less than or equal to the crystalline substance solubility in the polymer at temperature T a when there is no DSC dissolution endotherm identified. Thus, the method yields the upper and lower bounds for the equilibrium solubility at a given temperature or the upper and lower bounds for the equilibrium solubility temperature at a given crystalline substance concentration. The method improves accuracy of measurement near the glass transition temperature.

Method for evaluating the solubility of a crystalline substance in a polymer

A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning Calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices. The method relies on the detection of the dissolution endpoint of a drug/polymer mixture prepared by cryomilling.

METHOD FOR MANUFACTURING MERCAPTOCARBON ACIDS

Hardening of unsaturated fats, fatty acids or fatty acid esters

A process is disclosed for continuously hydrogenating unsaturated fats, fatty acids or fatty acid esters on a shaped catalyst in a solid bed. The reactants flow over the catalyst in the presence of a medium or solvent mixture in supercritical conditions. This leads to considerably improved activity and selectivity of the hydrogenation reaction compared with conventional trickle bed hydrogenation processes.

METHOD FOR PRODUCING THIOPHOSGEN

Catalyst and method for producing an amine

34Catalyst and method for producing an amineAbstract5 A process for preparing an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound selected from the group of am monia and primary and secondary amines, in the presence of a supported copper-, nickel- and cobalt-containing catalyst, wherein the catalytically active material of the catalyst, before the reduction thereof with hydrogen, comprises oxygen compounds of10 aluminum, of copper, of nickel and of cobalt, and in the range from 0.2 to 5.0% by weight of oxygen compounds of tin, calculated as SnO, and catalysts as defined above. No suitable figure

Process for the preparation of trichloromethanthiosulfenyl chloride

Torasemide-containing storage stable pharmaceutical preparations

Process for preparing primary amines using an unsupported cobalt catalyst

The invention relates to a process for preparing primary amines, which comprises hydrogenating at least one nitrile in an apparatus (V1) in the presence of an unsupported cobalt catalyst to obtain at least one primary amine, with recurrent or continuous addition of at least one compound (I) to the apparatus (V1), said compound (I) comprising at least one component selected from alkali metal, alkaline earth metal and rare earth metal.

Process for the continuous production of aqueous solutions of rhodanides of the alkali metals and of calcium, strontium and barium

Process for preparing an amine

Zusammensetzung und dosierform mit einer festen oder halbfesten matrix

Reaktor zur durchführung von hochdruckreaktionen, verfahren zur inbetriebnahme sowie verfahren zur durchführung einer reaktion

Verfahren zur beurteilung der löslichkeit eines kristallinen stoffes in einem polymer

Whisker Manufacturing, Detection, Response, and Compound Manufacturing Apparatus and Method

An invention for making productive uses of normally undesirable whiskers is provided. Embodiments of the invention include a variety of apparatuses and methods associated with forming and using whiskers as well as forming whisker compounds is disclosed. For example, whisker detection modules can be created which provide a whisker surveillance capability. The whisker detection modules can further be coupled with a whisker response system such as an alarm or insulating material dispersing system. Another aspect of the invention is providing a variety of environments or microenvironments with regard to a whisker forming structure to affect whisker creation such as maximizing whisker formation. Another example includes provision of a variety of embodiments for manufacturing compounds of whiskers of various metal and metal alloys, including structures and methods is provided. Whisker compounds produced using various embodiments of the invention can be used for various applications.

Whisker manufacturing, detection, response, and compound manufacturing apparatus and method

An invention for making productive uses of normally undesirable whiskers is provided. Embodiments of the invention include a variety of apparatuses and methods associated with forming and using whiskers as well as forming whisker compounds is disclosed. For example, whisker detection modules can be created which provide a whisker surveillance capability. The whisker detection modules can further be coupled with a whisker response system such as an alarm or insulating material dispersing system. Another aspect of the invention is providing a variety of environments or microenvironments with regard to a whisker forming structure to affect whisker creation such as maximizing whisker formation. Another example includes provision of a variety of embodiments for manufacturing compounds of whiskers of various metal and metal alloys, including structures and methods is provided. Whisker compounds produced using various embodiments of the invention can be used for various applications.

Whisker manufacturing, detection, response, and compound manufacturing apparatus and method

An invention for making productive uses of normally undesirable whiskers is provided. Embodiments of the invention include a variety of apparatuses and methods associated with forming and using whiskers as well as forming whisker compounds is disclosed. For example, whisker detection modules can be created which provide a whisker surveillance capability. The whisker detection modules can further be coupled with a whisker response system such as an alarm or insulating material dispersing system. Another aspect of the invention is providing a variety of environments or microenvironments with regard to a whisker forming structure to affect whisker creation such as maximizing whisker formation. Another example includes provision of a variety of embodiments for manufacturing compounds of whiskers of various metal and metal alloys, including structures and methods is provided. Whisker compounds produced using various embodiments of the invention can be used for various applications.

Verfahren zur herstellung eines amins

Türhalter

Verfahren zur herstellung von 5-nitrobenzofuranen

Herstellung von festen dosierungsformen unter verwendung eines vernetzten nicht- thermoplastischen tr gers

[UNK]

[UNK]

Verfahren zur Herstellung von 4-Methyl-penten-1

Verfahren zur Herstellung optisch aktiver Östran-Derivate

Verfahren zur herstellung aminoplastischer holzleime

Sulphamoyl-pyrimidines containing an asymmetric 1 carbon atom and having a blood sugar lowering activity

Peptide aus der sequenz des hpth (1-37)

Verfahren zur herstellung optisch aktiver 8,14-seco-oestranderivate

Verfahren zur Herstellung optisch aktiver 8,14-Seco-östranderivate

Verfahren zur Herstellung von Fäden und Folien aus Poly-bis-(1,2,4-triazolen)

Carboxylic acid derivatives and processes for their preparation and pharmaco logica l compositions incorporating such derivatives

Carboxylic acid derivatives and processes for their preparation and pharmaco logica l compositions incorporating such derivatives

2-Phenylhydrazino-imidazoline-(2), Verfahren zu deren Herstellung sowie diese enthaltende blutdrucksenkende Zubereitungen

Verfahren zur herstellung von 5 beta.h-6-ketosteroiden, 2 beta, 3 beta- diacetoxy-delta hoch 7 -5 beta-pregnen- 6-on-20-carbonsaeure, 2 beta, 3 beta, 14 alpha-trihydroxy-5 beta-pregn-7-en, 6,20- dion sowie praeparate mit hormonalen eigenschaften

Verfahren zur Verbesserung der Stabilität von Polyolefinen

Benzolsulfonylharnstoffe, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate

Sulphamoylphrimidines containing an asymmetric carbon atom and having a bloo sugar lowering activity

Sulphamoylphrimidines containing an asymmetric carbon atom and having a bloo sugar lowering activity

Sulphamoyl-pyrimidines containing an asymmetric 1 carbon atom and having a blood sugar lowering activity

[UNK]

Verfahren zur Aufarbeitung von Olefin-Polymerisaten

Verfahren zur Gewinnung von Schwefelkohlenstoff aus Trithian

Verfahren zur Herstellung von Mono- oder Biscarbodiimiden

Verfahren zur Verringerung des Thioharnstoffgehaltes von Alkali- und Erdalkalirhodaniden

[UNK]

Verfahren zur Herstellung von 4-Methylpenten-1

Verfahren zur Herstellung von 4-Methylpenten-1

Verfahren zur herstellung von magnetogrammtraegern

Torasemid enthaltende lagerstabile pharmazeutische zubereitungen

Verfahren zur Herstellung der neuen Metallverbindungen von Polyacyloxalamidrazonen

Metallverbindungen von Polyacyloxalamidrazonen

Metallverbindungen von Polyacyloxalamidrazonen

Verfahren zur herstellung von tetrachlorkohlenstoff aus benzol und chlor

Postupak za dobijanje vodenog rastvora amonijum rodanida

[UNK]

Postupak za dobijanje vodenog rastvora amonijum rodanida

[UNK]

Process forthe separation of oils from mixtures thereof with solid matter and asphalts, obtained as residues inthe destructive hydrogenation of distillable carbonaceous materials

Verfahren zur Verbesserung der Stabilität von Polyolefinen

Verfahren zur Herstellung von shwerentflammbaren Fäden, Fasern und Folien

[UNK]

芳香族またはヘテロ芳香族ニトリルを触媒的に調製するための方法

【課題】芳香族またはヘテロ芳香族ニトリルを触媒的に調製するための方法を提供する。 【解決手段】本発明は、ハロ芳香族化合物から出発して、場合によっては置換された芳香族またはヘテロ芳香族ニトリルを調製するための方法に関する。それらは、ヘテロ芳香族アミンの存在下に、ヘキサシアノ鉄（ＩＩ）酸カリウムまたはヘキサシアノ鉄（ＩＩＩ）酸カリウムとの銅触媒反応において反応させられる。 【選択図】なし

Verfahren zur Ruthenium-katalysierten Epoxidierung von Olefinen mit Wasserstoffperoxid

Preparados farmaceuticos que contienen torasemida.

Preparado farmacéutico sólido o semisólido estable al almacenamiento, que contiene torasemida esencialmente en forma no cristalina, como mínimo un componente ligante y en caso dado otras sustancias auxiliares farmacéuticamente aceptables, estando presente la torasemida en forma de aglomerados amorfos dispersos homogéneamente en una matriz de ligante con un tamaño <_ 1 mum o en forma de una solución sólida en una matriz de ligante.

Process for the asymmetric epoxidation of olefins

The present invention relates to a catalyst based on ruthenium complexes and to a process for the asymmetric epoxidation of olefins using catalysts based on ruthenium complexes.

Process for the Asymmetric Epoxidation of Olefins

The present invention relates to a catalyst based on ruthenium complexes and to a process for the asymmetric epoxidation of olefins using catalysts based on ruthenium complexes.

[UNK]

Verfahren zur Herstellung von Naphthalin durch pyrolytische Ringerweiterung von Indenhomologen

[UNK]

[UNK]

Verfahren zur Herstellung von trans-1,2-PoI ypentadien-1,3

Verfahren zur ruthenium-katalysierten epoxidierung von olefinen mit wasserstoffperoxid

Verfahren zum Trennen bzw Getrennt halten verschiedener Gasstrome in Mehrzo neneinschachtofen fur das Chlorieren von stuckigem Gut

Verfahren zur Herstellung von O, O-Dialkyl-S-thionothiolphosphorsaeureestern der Chinone oder Halogen-hydrochinone